Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic Cancer

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with poor prognosis and limited treatment options. While the majority of PDAC cases harbor KRAS mutations, approximately 8%-10% are KRAS wild-type (KRAS-WT). These KRAS-WT tumors often contain actionable mutations and gene fusions, making them more suitable for precision therapies. Identifying these molecular alterations is crucial for improving...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroendocrine Tumor Research Advances
• Share to Pancreatic and Hepatic Oncology Research
• Share to Pancreatitis Pathology and Treatment